In hematologic malignancies, aberrant TGF-β-SMAD signaling is implicated in ineffective hematopoiesis and leukemogenesis and evidence of TGF-β-mediated immune escape in leukemia/lymphoma is emerging [198–200]. Here, TGFB1 is linked to hematologic disorder.